D
Kymera Therapeutics, Inc. KYMR
$29.70 -$0.055-0.19% NASDAQ
Recommendation
Prev Close
$31.14
Volume
255,152
Avg Vol (90D)
668,625
Market Cap
$2.03B
Dividend & Yield
--
52-Week Range
$19.45 - $53.27
P/E (TTM)
--
EPS (TTM)
-$3.10
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Kymera Therapeutics (KYMR, $29.75) price exceeded its 50-day Moving Average on May 14, 2025
5/15/2025 - Tickeron - Stocks
Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff
5/14/2025 - SeekingAlpha
Bank of America Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price
5/14/2025 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from Guggenheim
5/14/2025 - MarketBeat
UBS Group Issues Pessimistic Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price
5/14/2025 - Ticker Report
Kymera Therapeutics (KYMR) Target Price Adjusted by UBS KYMR Stock News
5/13/2025 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS
5/13/2025 - MarketBeat
Kymera Therapeutics (KYMR) Target Price Revised by UBS KYMR Stock News
5/13/2025 - GuruFocus
Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week
5/13/2025 - Simply Wall St
Kymera Therapeutics price target lowered by $2 at UBS, here's why
5/13/2025 - The Fly
Kymera Therapeutics (KYMR, $32.17) Stochastic Oscillator left the oversold zone on May 12, 2025
5/13/2025 - Tickeron - Stocks
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts
5/12/2025 - Benzinga
Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from Guggenheim KYMR Stock News
5/12/2025 - GuruFocus
Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target Adjusted KYMR Stock News
5/12/2025 - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Receives Buy Rating from Guggenheim
5/12/2025 - Ticker Report
Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Strategic Changes KYMR Stock News
5/12/2025 - GuruFocus
Kymera Therapeutics price target lowered by $3 at B. Riley, here's why
5/12/2025 - The Fly
Kymera Therapeutics (KYMR) Receives a Buy from Oppenheimer
5/12/2025 - TipRanks Financial Blog
BofA Adjusts Price Target for Kymera Therapeutics (KYMR) KYMR Stock News
5/12/2025 - GuruFocus
BTIG Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
5/12/2025 - TipRanks Financial Blog
Kymera Therapeutics price target lowered to $55 from $60 at BTIG
5/12/2025 - TipRanks Financial Blog
Kymera Therapeutics price target lowered by $5 at BTIG, here's why
5/12/2025 - The Fly
Kymera Therapeutics price target lowered to $44 from $47 at BofA
5/12/2025 - TipRanks Financial Blog
Kymera Therapeutics price target lowered by $3 at BofA, here's why
5/12/2025 - The Fly
Kymera Therapeutics (NASDAQ:KYMR) Posts Earnings Results, Beats Expectations By $0.10 EPS
5/11/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$58.89M
EBITDA (TTM)
-$271.67M
EBIT (TTM)
-$278.23M
Net Income (TTM)
-$240.88M
Balance Sheet
Total Assets (Q)
$918.31M
Total Debt (Q)
$86.33M
Total Liabilities (Q)
$132.08M
Book Value Per Share (Q)
$12.08
Cash Flow
Cash from Operations (TTM)
-$234.06M
Cash from Investing (TTM)
-$24.86M
Cash from Financing (TTM)
$255.35M
Net Change in Cash (TTM)
-$3.56M
Filings
Filing Date
Friday, May 9, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.86
7-Day Total Return
-11.57%
30-Day Total Return
17.67%
60-Day Total Return
-20.02%
90-Day Total Return
-27.38%
Year to Date Total Return
-27.38%
1-Year Total Return
-15.37%
2-Year Total Return
-0.69%
3-Year Total Return
78.99%
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $19.45
52-week High
Sep 26, 2024 - $53.27
Valuation
Market Cap
$2.03B - Mid Cap
Enterprise Value
$1.34B
Price/Sales (TTM)
42.38
Price/Book (Q)
2.58
Dividends and Shares
Shares Outstanding
80.15M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kymeratx.com
Phone Number
857 285 5300
Address
500 North Beacon Street
Watertown, MA 02472
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by... more
NASDAQ 05/15/2025 2:47PM Eastern Quotes delayed